Venetoclax

Manufactured by Selleck Chemicals

Sourced in United States, Germany

Venetoclax is a small molecule inhibitor of the B-cell lymphoma 2 (BCL-2) protein. It is designed to selectively inhibit the anti-apoptotic activity of the BCL-2 protein, which is often overexpressed in certain types of cancer cells.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Venetoclax (ABT-199) (23 citations)

84 protocols using venetoclax

Cardiac Remodeling Intervention in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Male C57BL/6J mice aged 10 weeks were purchased from Shanghai SLAC Laboratory Animal CO, LTD (China). The experimental procedures were approved by the Institutional Animal Ethical Committee of Luodian hospital of Baoshan District. The experiments were proceeded according to NIH guidelines for Care and Use of Laboratory Animals (NIH, 8th Edition, 2011). The mice were maintained in individually ventilated cages (at 22°C, 12 h light/dark cycle) with free access to standard laboratory chow. 40 rats were randomly divided into 4 groups (10 for each group), which were, namely, Sham group, TAC group, TAC+ LY294002 group, and TAC + Venetoclax group.
TAC operation was performed as a previous report [21 ]. Briefly, for the TAC group, after carotid arteries explosion and 60%-75% diameter of ligation, mice were administrated with normal saline (NS, 1 ml/day) for 8 weeks; for the TAC + LY294002 group, mice were treated with LY294002 (20 mg/kg/day, Sigma, USA) for 8 weeks by intraperitoneal injections; for the TAC+ Venetoclax group, mice were treated with Venetoclax (100 mg/kg/day, Selleckchem) for 8 weeks by oral gavage.
After administration of TAC operation, mice were maintained for another 8 weeks. Subsequently, the hearts were collected and fixed with 10% neutral formalin and preserved in -80°C for further research.

Meng X., Cui J, & He G. (2021). Bcl-2 Is Involved in Cardiac Hypertrophy through PI3K-Akt Pathway. BioMed Research International, 2021, 6615502.

+ Open protocol

+ Expand

Venetoclax Cytotoxicity Assay in NALM-6

Check if the same lab product or an alternative is used in the 5 most similar protocols

pCYB5Aalt NALM-6 and empty vector controls were treated with Venetoclax (SelleckChem, München, Germany) and seeded in quintets for each concentration of Venetoclax (0, 0.2, 0.5, 1, 5, 10 μM). 1 × 10⁵ cells per well were seeded in 90 μl medium and incubated at 37 °C, 5% CO₂. After 72 h, 10 μl of WST-1 reagent was added to each well and cells were incubated at same conditions for 3 h to allow for reduction of WST-1 to formazan by the electron transport chain of viable cells. Then, absorbance was measured using a Sunrise microplate absorbance reader (Tecan, Männerdorf, Switzerland) at 450 nm with a reference wavelength of 620 nm. Raw absorbance measurements were normalised to untreated control samples, after subtracting WST-1 absorbance measurements in wells only containing medium.

Bartsch L., Schroeder M.P., Hänzelmann S., Bastian L., Lázaro-Navarro J., Schlee C., Tanchez J.O., Schulze V., Isaakidis K., Rieger M.A., Gökbuget N., Eckert C., Serve H., Horstmann M., Schrappe M., Brüggemann M., Baldus C.D, & Neumann M. (2022). An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse. BMC Genomic Data, 23, 30.

+ Open protocol

+ Expand

Cell Culture Materials and Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPMI 1640 medium and penicillin/streptomycin were purchased from Lonza (Verviers, Belgium), amphotericin B from PAN-Biotech (Aidenbach, Germany), fetal calf serum (FCS) from Life Technologies (Carlsbad, CA) and venetoclax, ponatinib, and selinexor from Selleckchem (Houston, TX). Gemtuzumab-ozogamicin (GO) was obtained from Pfizer (New York, NY). Stock solutions of drugs were prepared by dissolving in dimethylsulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO). ³H-thymidine was purchased from Perkin Elmer (Boston, MA). A specification of monoclonal antibodies (mAb) used in this study is shown in Supplementary Table S1.

Eisenwort G., Sadovnik I., Keller A., Ivanov D., Peter B., Berger D., Stefanzl G., Bauer K., Slavnitsch K., Greiner G., Gleixner K.V., Sperr W.R., Willmann M., Sill H., Bettelheim P., Geissler K., Deininger M., Rülicke T, & Valent P. (2021). Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia. Leukemia, 35(11), 3176-3187.

+ Open protocol

+ Expand

Chemical Procurement for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

All non-drug chemicals were purchased from Sigma Aldrich (St. Louis, MO). Solvents were purchased from Acros organics (Morris Plains, NJ). All drugs were purchased from LC-Laboratories (Woburn, MA), except glibenclamide, glimepiride, and cyclosporine which were purchased from Sigma Aldrich, TAK632 from AdooQ Bioscience (Irvine, CA), and talazoparib, fulvestrant, venetoclax, selumetinib, and taselisib from Selleckchem (Houston, TX).

Shamay Y., Shah J., Işık M., Mizrachi A., Leibold J., Tschaharganeh D.F., Roxbury D., Budhathoki-Uprety J., Nawaly K., Sugarman J.L., Baut E., Neiman M.R., Dacek M., Ganesh K.S., Johnson D.C., Sridharan R., Chu K.L., Rajasekhar V.K., Lowe S.W., Chodera J.D, & Heller D.A. (2018). Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines. Nature materials, 17(4), 361-368.

+ Open protocol

+ Expand

Preparation of Iron Chelation Agents

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Deferoxamine (Novartis Pharma SAS) was dissolved in sterile distilled water and deferasirox (Selleckchem S1712), was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 300 and 50 mmol/L, respectively. Ironomycin was a kind gift of Raphaël Rodriguez team (11 (link)), this compound was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mmol/L. Other reagents: erastin (Selleckchem S7242, 10 mmol/L in DMSO), ferrostatin-1 (Selleckchem S7243, 50 mmol/L in DMSO), Q-VD Oph (SelleckChem S7311, 10 mmol/L in DMSO, 30′ pretreatment), iron(III) chloride hexahydrate (31232 Sigma Aldrich, 0.1 mol/L in water, 4 hours after treatment), reduced gluthatione GSH (Sigma Aldrich G4251, 0.1 M in PBS) H₂O₂ (Sigma Aldrich 216763), mafosfamide (surrogate of cyclophosphamide, Santa Cruz ChemCruz SC-211761, 10 mmol/L in saline water), gemcitabine (Sellekchem S1149, 50 mmol/L in saline water), doxorubicin (Sellekchem S1208, 20 mmol/L in DMSO), CldU (Abcam ab213715, 20 mmol/L), IdU (Abcam ab142581, 2 mmol/L), 3-methyl adenine (Merck, #189490), β-mercaptoethanol (Sigma, M3148), staurosporine (Selleckchem, S1421), ketokonazole (Sigma, UC280), Avasimibe (from Sigma, PZ0190), ibrutinib (from Sellekchem S2680), entospletinib (from Selleckchem, S7523), venetoclax (from Sellekchem, S8048), AZD-5991 (from Selleckchem, S8643), and A1155463 (from TargetMol, T6748).

Devin J., Cañeque T., Lin Y.L., Mondoulet L., Veyrune J.L., Abouladze M., Garcia De Paco E., Karmous Gadacha O., Cartron G., Pasero P., Bret C., Rodriguez R, & Moreaux J. (2022). Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma. Cancer Research, 82(6), 998-1012.

+ Open protocol

+ Expand

Multimodal Profiling of Extracellular Vesicles

Check if the same lab product or an alternative is used in the 5 most similar protocols

Daporinad (catalog no. S2799), venetoclax (catalog no. S8048), OSI-027 (catalog no. S2624), PI-103 (catalog no. S1038), and doxycycline (catalog no. S5159) were obtained from Selleck Chemicals (Houston, TX, USA). CCCP (catalog no. HY-100941) and metformin hydrochloride (catalog no. HY-17471A) were purchased from MedChemExpress (Greenville, SC, USA). Anti-CD63 (ab59479), anti-CD81 (ab79559), and anti-TSG101 (ab125011) antibodies for immunoblotting and flow cytometry were purchased from Abcam (Cambridge, UK).

Wu Z., Sun H., Wang C., Liu W., Liu M., Zhu Y., Xu W., Jin H, & Li J. (2020). Mitochondrial Genome-Derived circRNA mc-COX2 Functions as an Oncogene in Chronic Lymphocytic Leukemia. Molecular Therapy. Nucleic Acids, 20, 801-811.

+ Open protocol

+ Expand

Cell Line Authentication and Drug Treatment Protocol for KRAS-Mutant NSCLC

Check if the same lab product or an alternative is used in the 5 most similar protocols

All human KRAS-mutant NSCLC cell lines were purchased from ATCC, except for LU99 and LU65, obtained from JCRB Cell Bank, and H2122, obtained in house. Cells were maintained in RPMI 1640 medium supplemented with 10% FBS and 1% streptomycin/penicillin at 37°C under 5% CO₂. Human cell-line authentication was performed through short tandem repeat (STR) marker genotyping. All cell lines tested negative for Mycoplasma contamination using the MycoAlert Detection Kit (Lonza, catalog LT07-318). For drug treatments, eIF4A inhibitor eFT226 and KRAS G12C inhibitor MRTX849 were purchased from MedChemExpress; MEK inhibitor trametinib was purchased from LC Laboratories; BCL-xL/BCL-2 inhibitor navitoclax, BCL-2 inhibitor venetoclax, and CDK4/6 inhibitor palbociclib were purchased from Selleckchem; and MCL1 inhibitor S63845 was purchased from Chemietek.

Nardi F., Perurena N., Schade A.E., Li Z.H., Ngo K., Ivanova E.V., Saldanha A., Li C., Gokhale P.C., Hata A.N., Barbie D.A., Paweletz C.P., Jänne P.A, & Cichowski K. (2023). Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. The Journal of Clinical Investigation, 133(16), e167651.

+ Open protocol

+ Expand

Screening BRCA1 and BCL2 in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

For BRCA1 screens in MELJUSO cells, cisplatin (BioVision, 1550) was diluted in 0.9% NaCl and was screened at 1 μM. For BCL2 screens in MOLM13 cells, Venetoclax (Selleckchem, S8048) was diluted in DMSO and was screened at 62.5 nM.

Sangree A.K., Griffith A.L., Szegletes Z.M., Roy P., DeWeirdt P.C., Hegde M., McGee A.V., Hanna R.E, & Doench J.G. (2022). Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2. Nature Communications, 13, 1318.

+ Open protocol

+ Expand

Lintuzumab and Venetoclax for AML Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Humanized anti‐CD33 antibody, lintuzumab, was provided by Actinium Pharmaceuticals, Inc.¹⁷ Venetoclax was purchased from Selleckchem (Cat. No.: S8048). For animal studies, Venetoclax was formulated in 60% Phosal 50 PG (Cat. No.: NC0130871, Lipoid, Thermo Fisher Scientific), 30% polyethylene glycol 400 (Cat. No.: 81172, Sigma‐Aldrich), and 10% ethanol. ²²⁵Ac in anhydrous nitrate form was procured from Oak Ridge National Laboratory, USA. Bifunctional chelating agent p‐SCN‐Bn‐DOTA (DOTA) was purchased from Macrocyclics (Lot No.: B20510021). AML cell lines MOLM‐13 (DSMZ No.: ACC 554) and OCI‐AML3 (DSMZ No.: ACC 582) were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and U937 from the ATCC (Cat. No.: CRL‐1593.2). All cell lines were cultured in RPMI‐1640 (Cat no: SH30255.01, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Sigma‐Aldrich) and 1% antibiotic/antimycotic (Cat. No.: 15–240–062, Thermo Fisher Scientific). Cells were kept at 37⁰C in a 5% CO₂ incubator. CD33 expression by the AML cell lines was determined by flow cytometry. Cells were stained with PE‐conjugated anti‐human CD33 or isotype control mAbs (Clone No.: HIM3‐4, Cat. No.: 12–0339–42, BD PharMingen).

Garg R., Allen K.J., Dawicki W., Geoghegan E.M., Ludwig D.L, & Dadachova E. (2020). 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Medicine, 10(3), 1128-1140.

+ Open protocol

+ Expand

Myeloma Cell-Stromal Cell Coculture Assay

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cocultures were seeded into 384 well plates (Corning) with the Multidrop Combi (Thermo Scientific). 800 stromal cells were seeded and incubated overnight. 17 hours later, 700 myeloma cells were added on top of the stromal cells. On the third day, 24 hours after the addition of myeloma cells, cocultures were treated with tofacitinib (LC Laboratories), ruxolitinib (Selleck Chemicals), JAK3i,^{20 (link)} or IL-6 blocking antibody (R&D Systems). For drug combination studies, on the fourth day, melphalan (Sigma Aldrich), carfilzomib (Selleck Chemicals), or venetoclax (Selleck Chemicals) were additionally added to cocultures. On the fifth day, myeloma cell viability was detected with the addition of luciferin (Gold Biotechnology) and read for luminescence on Glomax Explorer plate reader (Promega) as previously described.^{21 (link)} For monoculture studies cell viability was measured using CellTiter-Glo reagent (Promega). All measurements were performed in quadruplicate. All viability data are reported as normalized to dimethyl sulfoxide (DMSO)-treated cell line in monoculture.

Lam C., Ferguson I.D., Mariano M.C., Lin Y.H., Murnane M., Liu H., Smith G.A., Wong S.W., Taunton J., Liu J.O., Mitsiades C.S., Hann B.C., Aftab B.T, & Wiita A.P. (2018). Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica, 103(7), 1218-1228.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!